Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials

Mourad, Nathalie; Mounier, Nicolas; Brière, Josette; Raffoux, Emmanuel; Delmer, Alain; Feller, Alfred C.; Meijer, Chris J.L.M.; Émile, Jean-François; Bouabdallah, Réda; Bosly, André; Diébold, J; Haı̈oun, Corinne; Coiffier, Bertrand; Gisselbrecht, Christian; Gaulard, Philippe

doi:10.1182/blood-2007-08-105759

Cited by 296 publications

(342 citation statements)

References 55 publications

Supporting

Mentioning

301

Contrasting

Unclassified

Order By: Relevance

“…This is consistent with the reported low incidence of skin rash in India (only 5%) [6]. This case had the typical histopathological pattern of lymph node involvement (Pattern III) [7] and it also fulfills 4 out of 5 histological criteria suggested for the diagnosis of AITL [8].…”

Section: Discussionsupporting

confidence: 89%

A Synchronous Presentation of AITL with Adenocarcinoma of Lung

Karunakaran¹

2016

Int J Immunother Cancer Res

View full text Add to dashboard Cite

Angioimmunoblastic T-cell lymphoma (AITL) is a frequent subtype of peripheral T -cell lymphoma (PTCL) characterized by generalized lymphadenopathy, hepatosplenomegaly, and frequent Bsymptoms. Extranodal manifestations are quite common in this subtype of Non Hodgkins Lymphoma which is characterized by frequent skin involvement. However, the extranodal disease should be evaluated thoroughly and a tissue diagnosis must be obtained to confirm lymphomatous involvement when the presentation is not classical. Here we report a case of AITL who presented with lung mass suspected to be due to lymphomatous involvement, but turned out to be a synchronous presentation of an adenocarcinoma of the lung. The possible relation between the two conditions is also elucidated.

show abstract

Section: Discussionsupporting

confidence: 89%

A Synchronous Presentation of AITL with Adenocarcinoma of Lung

Karunakaran¹

2016

Int J Immunother Cancer Res

View full text Add to dashboard Cite

show abstract

“…CD10 expression is seen in roughly 70% of angioimmunoblastic T-cell lymphoma cases and although useful for detecting angioimmunoblastic T-cell lymphoma in most non-nodal sites, it has less utility in skin biopsies. 27,41,42,43,56 We do not know exactly the percentage of mycosis fungoides cases that are CD10( þ ) but based on our flow cytometry data, roughly 16.7% (6/36) of mycosis fungoides cases were found to express CD10. An evaluation of a large number of mycosis fungoides cases for follicular center helper T-cell markers including CD10 and Bcl-6 would be necessary to determine more precisely the frequency of reactivity of these markers and their relationship to one another and, ultimately, their utility in distinguishing mycosis fungoides from angioimmunoblastic T-cell lymphoma.…”

Section: Discussionmentioning

confidence: 84%

“…[38][39][40] The neoplastic T cells in angioimmunoblastic T-cell lymphoma express the follicular center helper T-cell markers CD10, PD-1, and CXCL-13 in the majority of cases. 27,[41][42][43] Angioimmunoblastic T-cell lymphoma is also notable for an association with EBV as 70% or more angioimmunoblastic T-cell lymphoma lesions contain EBV( þ ) B cells, a finding helpful in establishing the diagnosis. 44 Peripheral T-cell lymphomas may express follicular center helper T-cell markers with or without a follicular growth pattern.…”

mentioning

confidence: 99%

Follicular center helper T-cell (TFH) marker positive mycosis fungoides/Sezary syndrome

et al. 2013

View full text Add to dashboard Cite

“…Only 14% presented with an IPI score of 0 or 1. In a French study of 157 patients, the median age was 62 years, 81% of the patients had Stage III or IV disease, 72% had Bsymptoms, and 60% were men [33].…”

Section: Angioimmunoblastic T-cell Lymphomamentioning

confidence: 99%

“…One-hundred and forty-seven patients in a large French experience received some form of anthracycline-based chemotherapy, with the most common being ACVBP in younger patients [33]. A complete response was achieved in 46% of the patients, but 20% of the treated patients developed severe infections during therapy.…”

Section: Angioimmunoblastic T-cell Lymphomamentioning

confidence: 99%

The aggressive peripheral T‐cell lymphomas: 2015

Armitage

2015

American J Hematol

View full text Add to dashboard Cite

Background: T‐cell lymphomas make up approximately 10%–15% of lymphoid malignancies. The frequency of these lymphomas varies geographically, with the highest incidence in parts of Asia.Diagnosis: The diagnosis of aggressive peripheral T‐cell lymphoma (PTCL) is usually made using the World Health Organization classification. The ability of hematopathologists to reproducibly diagnosis aggressive PTCL is lower than that for aggressive B‐cell lymphomas, with a range of 72%–97% for the aggressive PTCLs.Risk Stratification: Patients with aggressive PTCL are staged using the Ann Arbor Classification. Although somewhat controversial, positron emission tomography scans seem to be useful as they are in aggressive B‐cell lymphomas. The most commonly used prognostic index is the International Prognostic Index. The specific subtype of aggressive PTCL is an important risk factor, with the best survival seen in anaplastic large‐cell lymphoma—particularly young patients with the anaplastic lymphoma kinase positive subtype.Risk‐Adapted Therapy: Anaplastic large‐cell lymphoma is the only subgroup to have a good response to a CHOP‐like regimen. Angioimmunoblastic T‐cell lymphoma has a prolonged disease‐free survival in only ∼20% of patients, but younger patients who have an autotransplant in remission seem to do better. PTCL‐not otherwise specified is not one disease. Anthracycline‐containing regimens have disappointing results, and a new approach is needed. Natural killer/T‐cell lymphoma localized to the nose and nasal sinuses seems to be best treated with radiotherapy‐containing regimens. Enteropathy‐associated PTCL and hepatosplenic PTCL are rare disorders with a generally poor response to therapy, although selected patients with enteropathy‐associated PTCL seem to benefit from intensive therapy. Am. J. Hematol. 90:666–673, 2015. © 2015 Wiley Periodicals, Inc.

show abstract

Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials

Cited by 296 publications

References 55 publications

A Synchronous Presentation of AITL with Adenocarcinoma of Lung

A Synchronous Presentation of AITL with Adenocarcinoma of Lung

Follicular center helper T-cell (TFH) marker positive mycosis fungoides/Sezary syndrome

The aggressive peripheral T‐cell lymphomas: 2015

Contact Info

Product

Resources

About